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Abstract
From January 1 to April 3, 2015, 159 people from 18 states and the District of Columbia were 
reported as having measles. Most cases are part of an outbreak linked to a California amusement 
park. Because measles was eliminated in the United States in 2000, most U.S. clinicians are 
unfamiliar with the condition. We reviewed information on the current outbreak, measles 
manifestations, diagnostic methods, treatment, and infection-control recommendations. To 
identify information on measles and pregnancy, we reviewed reports with 20 or more measles 
cases during pregnancy that included data on effects on pregnant women or pregnancy outcomes. 
These reports were identified through MEDLINE from inception through February 2015 using the 
following strategy: (((pregnan*) AND measles) AND English[Language]) NOT 
review[Publication Type]. Reference lists also were reviewed to identify additional articles. 
Pregnant women infected with measles are more likely to be hospitalized, develop pneumonia, and 
die than nonpregnant women. Adverse pregnancy outcomes, including pregnancy loss, preterm 
birth, and low birth weight, are associated with maternal measles; however, the risk of congenital 
defects does not appear to be increased. No antiviral therapy is available; treatment is supportive. 
Early identification of possible cases is needed so that appropriate infection control can be 
instituted promptly. The recent measles outbreak highlights the role that obstetric health care 
providers play in vaccine-preventable illnesses; obstetrician–gynecologists should ensure that 
patients are up to date on all vaccines, including measles-containing vaccines, and should 
recommend and ideally offer a measles-containing vaccine to women without evidence of measles 
immunity before or after pregnancy.
From January 1 to April 3, 2015, 159 people from 18 states and the District of Columbia 
have been reported as having measles.1 Most cases are part of a large, ongoing outbreak 
linked to a California amusement park. Because of a highly successful vaccination program, 
measles elimination (defined as absence of endemic disease transmission, ie, a chain of 
transmission that continues for 12 or more months)2 was declared in the United States in 
2000. However, elimination does not suggest that no cases will occur: measles is endemic in 
many countries throughout the world, and outbreaks continue to occur in the United States 
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when unvaccinated persons are exposed to imported measles virus either during 
international travel or by foreign visitors infected with measles.3 Since 2000, the annual 
number of measles cases in the United States has ranged from a low of 37 in 2004 to a high 
of 668 in 2014 (Fig. 1).1 Before measles vaccination was available, measles was primarily a 
childhood disease; however, since 2000, about 40% of cases occurred in adults, with about a 
quarter among persons 20–39 years of age.2
In previous studies, pregnant women have been shown to be at increased risk for 
complications associated with measles, including adverse pregnancy outcomes.4–6 
Therefore, it is essential that obstetric health care providers are aware of measles and its 
effects on pregnant women and their newborns. Here we review the clinical features, 
diagnostic methods, infection-control measures, and treatment of measles, as well as 
information on the effects of measles during pregnancy and recommendations for pregnant 
women and newborns. To identify information on measles and pregnancy, we reviewed 
reports with 20 or more measles cases during pregnancy that included data on effects of 
measles on pregnant women or pregnancy outcomes. These reports were identified through 
MEDLINE from inception through February 2015 using the following search strategy: 
(((pregnan*) AND measles) AND English[Language]) NOT review[Publication Type]. 
Reference lists from selected articles were also reviewed to identify additional articles.
MEASLES
Measles (rubeola) is a highly contagious respiratory illness caused by a single-stranded, 
enveloped RNA virus that is a member of the genus Morbillivirus in the Paramyxoviridae 
family.3 Measles is a condition clinically and virologically distinct from rubella (sometimes 
referred to as German or 3-day measles). Persons infected with measles typically present 
with a prodrome of high fever and malaise and cough, coryza (runny nose), and 
conjunctivitis (the “three Cs”). The measles prodrome typically occurs 3–4 days before 
appearance of the rash. Near the end of the prodrome, Koplik’s spots (small white lesions on 
an erythematous base) may appear on the buccal mucosa, followed by a maculopapular rash 
that typically spreads from the head to the trunk to the lower extremities. The measles rash 
gradually fades, first from the face and last from the lower extremities. The average 
incubation period of measles (from exposure until prodrome onset) is 10–12 days; onset of 
the rash typically occurs about 14 (range 7–21) days after exposure.3 Treatment of measles 
is supportive; no specific antiviral therapy is available.
Complications and death from measles are more common in infants, young children, and 
adults compared with older children and adolescents.3 Measles complications include 
pneumonia and encephalitis. In addition, subacute sclerosing panencephalitis, a degenerative 
disease of the central nervous system characterized by intellectual decline and behavior 
changes, followed by seizures, dementia, and death, can occur on average 4–10 years after 
acute measles illness, although latency periods have ranged from less than a year to several 
decades.7 Incidence has been estimated to be 4–11 cases per 100,000 cases of measles.7
Before licensure of the live attenuated measles vaccine in 1963, approximately 3–4 million 
persons were estimated to have been infected with measles in the United States each year; of 
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those, 48,000 were hospitalized and 500 died.3 The Centers for Disease Control and 
Prevention recommends that the first dose of measles-containing vaccine (measles–mumps–
rubella (MMR) vaccine or measles–mumps–rubella–varicella vaccine—both referred to 
hereafter as MMR vaccine) be given at 12 through 15 months of age, with a second dose 
recommended at 4 through 6 years of age or at least 28 days after the first dose.3 The first 
dose of measles-containing vaccine is about 93% effective at preventing measles if exposed 
to the virus; two doses are about 97% effective. Immunity appears to be long-term and 
probably life-long in most people.3
Measles is a highly contagious illness transmitted by direct contact with infectious droplets 
or by airborne spread. Up to 90% of susceptible persons develop measles after exposure.3 
The virus continues to be infectious on surfaces and in the air for up to 2 hours. Persons with 
measles are infectious from 4 days before through 4 days after rash onset and should be 
isolated during that period.
EFFECTS OF MEASLES IN THE PREGNANT WOMAN
Pregnant women are at increased risk of morbidity and mortality associated with measles 
based on many studies (Table 1). Many of these studies are case series and lack comparison 
groups, but two studies that include comparison groups of nonpregnant women with measles 
deserve particular attention. In a study by Eberhart-Phillips et al,5 58 pregnant women with 
measles were identified in an outbreak in Los Angeles during the period from 1988–1991. 
Compared with 748 nonpregnant women with measles, pregnant women were significantly 
more likely to be hospitalized, to develop pneumonia, and to die. In a study in Saudi Arabia 
in 1993,6 pregnant women with measles were significantly more likely to be hospitalized 
than those who were not pregnant. Fever and elevated liver enzymes were also more 
common among pregnant women with measles than among nonpregnant women. Although 
these studies suggest that pregnant women with measles are more likely to be hospitalized 
and many hospitalized women had pneumonia, the reasons for hospital admission usually 
were not specified. Some of these studies also included women infected during the 
postpartum period (Table 1), but numbers of cases are too small to assess whether 
postpartum women are also at high risk.
EFFECTS OF MEASLES ON THE FETUS
Adverse pregnancy outcomes also have been commonly reported among pregnant women 
with measles in several studies (Table 1). Analyses that include a comparison group of 
pregnant women without measles are the most informative. In a cohort study from New 
York City during the period from 1957–1964,8 measles was associated with an increased 
frequency of low birth weight (less than 2,500 g), which appeared to be due to preterm 
labor. However, in this cohort, pregnancy loss was not more frequent among measles-
infected pregnant women compared with pregnant women without measles.9 In the study 
from Saudi Arabia,6 neonates born to women with measles were significantly more likely to 
be born preterm, to be admitted to the neonatal intensive care unit, and to have longer 
intensive care unit stays than neonates born to women without measles. Rates of 
spontaneous abortion, intrauterine fetal demise, and neonatal mortality were higher among 
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pregnant women with measles, but these findings were not statistically significant. In a study 
from Namibia,4 women with measles were significantly more likely to have spontaneous 
abortion, intrauterine fetal demise, or neonates with low birth weight than women without 
measles.
Because maternal rubella infection is a well-recognized cause of congenital defects, 
concerns have been raised regarding whether measles might also be teratogenic. In a case 
series from Greenland of 300 liveborn neonates prenatally exposed to measles in 10 
epidemics during the period from 1951–1962,10 eight (2.7%) had congenital malformations, 
a rate not higher than expected. However, 5 of 58 (9%) neonates with first-trimester 
exposures had severe congenital malformations, leading the authors to speculate that 
maternal measles infection could cause congenital defects, although no specific pattern of 
malformations was seen and no comparison group of non–measlesinfected women was 
included. Subsequent studies have not substantiated this association (Table 1). In two studies 
that included comparison groups of neonates born to women without measles,6,11 no 
differences were seen in the rate of congenital defects among neonates born to women with 
and without measles during pregnancy.
TRANSMISSION OF MATERNAL MEASLES TO THE FETUS (CONGENITAL 
MEASLES)
Transmission of measles virus from a pregnant woman to her fetus (congenital measles) has 
been reported in neonates born to women who had measles within 10 days of delivery.12 
Congenital measles is defined as presence of the rash at birth or within the first 10 days of 
life (this early timing excludes transmission from mother to newborn postdelivery) in a 
newborn whose mother was infected with measles late in pregnancy. Provision of pooled 
human immune globulin after delivery can decrease the risk of congenital measles; however, 
cases have been observed even after its receipt, although these cases may be milder.12 
Infants who develop congenital measles are at increased risk for mortality and for subacute 
sclerosing panencephalitis, which is more common when measles is diagnosed in infancy.7 
In addition, subacute sclerosing panencephalitis in newborns infected with measles either 
congenitally or shortly after birth appears to be more severe, with a shorter latency and 
rapidly progressive course.7
DOCUMENTATION OF MEASLES IMMUNITY
A two-dose MMR vaccine schedule has been recommended by the Advisory Committee on 
Immunization Practices and the American Academy of Pediatrics since 1989.3 Despite these 
national vaccine recommendations, obstetric health care providers cannot assume that 
pregnant women in the United States were vaccinated with MMR vaccine in childhood. 
Recent studies have documented high levels of nonimmunity to measles among pregnant 
women in the United States; in a study by Haas et al of women presenting for prenatal care 
in 2004, 16.5% of women were not immune to measles. In that study, three quarters of 
women did not recall whether they had received the recommended second MMR 
vaccination, and even among those who reported receiving a second dose of vaccine, only 
85% were measles-immune,13 raising questions about maternal report of vaccination. One 
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might assume that rubella immunity (a routine part of prenatal care) could serve as a 
surrogate for measles immunity; however, in a study in Iowa, only 88% of those who were 
rubella-immune were also immune to measles, leading these authors to recommend that 
pregnant women who are exposed to measles be tested to document measles immunity.14 
These results emphasize the importance of written documentation of MMR vaccination.
RECOMMENDATIONS (Updates Available at http://www.cdc.gov/measles/
hcp/)
Recommendations for routine vaccination:
• The American College of Obstetricians and Gynecologists recommends that health 
care providers review vaccination history as a routine part of a woman’s general 
preventive health care.15 Health care providers should recommend and, if possible, 
offer indicated vaccinations. Studies have shown that health care provider 
recommendation and offer of vaccines are strong factors in determining whether a 
patient gets vaccinated.15 Additional information on integrating immunizations into 
clinical practice is included at www.immunizationforwomen.org.
• Health care providers should document that they provided counseling regarding 
indicated vaccines and the patient’s decision (accepted, refused, or intend to receive 
indicated vaccines at another facility) regarding these vaccines.15
• As part of the vaccination history review, health care providers should ensure that 
all patients have documentation of measles immunity. Acceptable evidence of 
measles immunity includes written documentation of receipt of live measles virus–
containing vaccine (two doses for adults at increased risk for exposure, such as 
students attending colleges or other post–high school educational institutions, 
health care personnel, and international travelers, and one dose for other adults 
aged 18 years or older), laboratory evidence of measles immunity (ie, presence of 
measles-specific immunoglobulin [Ig] G antibody in serum; equivocal results 
should be considered negative), laboratory confirmation of disease, or birth before 
1957 (persons born before 1957 are presumed to be immune owing to natural 
measles infection).3 In an outbreak setting in which community-wide transmission 
is occurring among adults, a second dose should be considered for adults who have 
received only one dose.
• If documentation of measles immunity is not available, women should be asked if 
they are pregnant or might become pregnant in the next 4 weeks. Because MMR 
vaccine is a live vaccine, women who are pregnant or planning to become pregnant 
should not be vaccinated. Others should be vaccinated after they are counseled to 
avoid becoming pregnant for the next 4 weeks because of the theoretical risk of 
infection with one of the live components of the vaccine.3 Routine pregnancy 
testing of women of reproductive age is not recommended before giving MMR 
vaccine.
• If a woman inadvertently receives the MMR vaccine during pregnancy or becomes 
pregnant within 4 weeks after receiving the vaccine, she should be counseled about 
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the theoretical risk of congenital rubella syndrome associated with receiving a 
rubella-containing vaccine; however, studies on neonates born to women who have 
inadvertently received MMR vaccination during pregnancy have not shown an 
increased risk of adverse outcomes.3 Because measles infection during pregnancy 
does not appear to be associated with congenital defects, exposure to the measles 
component is not believed to be of concern. MMR vaccination during pregnancy 
should not be considered a reason for pregnancy termination.3
• Pregnant women without evidence of measles immunity or who are rubella-
nonimmune should receive MMR vaccine after delivery—ideally before they are 
discharged from the hospital.3 Women who receive the MMR vaccine during the 
postnatal period can breastfeed without risk to their newborns.
Recommendations for persons who work in health care facilities:
• All persons who work in health care facilities should have presumptive evidence of 
immunity to measles, which includes any of the following: 1) written 
documentation of vaccination with 2 doses of live measles or MMR vaccine (first 
dose at 1 year of age or older, second dose at least 28 days after the first dose), 2) 
laboratory evidence of immunity, 3) laboratory confirmation of disease, or 4) birth 
before 1957.16
• Health care facilities should ensure that information on measles immunity of 
personnel is documented and readily available.
• If measles exposure occurs in a health care facility, health care personnel without 
evidence of measles immunity should be excluded from the health care setting from 
5 through 21 days after exposure.16
Recommendations for pregnant women without evidence of measles immunity exposed to 
measles:
• Because of their increased risk for measles-related morbidity and mortality, 
pregnant women without evidence of measles immunity who are exposed to 
measles should receive intravenous immune globulin at a dose of 400 mg/kg within 
6 days of exposure. Intravenous administration is recommended so that doses are 
high enough to reach levels of measles antibodies expected to be protective.3 A 
rapid IgG antibody test can be used to document measles immunity, provided that 
immune globulin administration is not delayed.3
Recommendations for pregnant women with suspected or known measles:
• Measles should be considered in patients presenting with fever, rash, and other 
symptoms consistent with measles (eg, cough, coryza, and conjunctivitis). Ill 
patients should be asked about recent international travel, recent visits to venues 
frequented by international visitors, and history of measles illness in their 
communities.
• Patients with suspected measles should be isolated promptly in an airborne 
infection isolation room, and a facemask should be placed on the patient if feasible. 
All health care personnel caring for the patient should have evidence of measles 
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immunity.3,16 Appropriate personal protective equipment (respiratory protection at 
least as protective as a fit-tested N95 respirator) should be used by all health care 
providers caring for the patient, even those with documented immunity.1 Cases of 
suspected measles should be reported immediately to the local health department.
• The most common methods for confirming measles infection are detection of 
measles-specific IgM antibody and measles RNA by real-time polymerase chain 
reaction.1 Health care providers should collect both a serum sample and a throat (or 
nasopharyngeal) swab; collection of urine also might be helpful because testing 
both respiratory and urine samples can increase the likelihood of measles virus 
detection. Collection of virologic specimens allows viral genotyping. The local 
health department should be contacted for information about submitting specimens 
for testing. Additional information on laboratory testing is available at the Centers 
for Disease Control and Prevention website: http://www.cdc.gov/measles/lab-tools/
index.html.
• Pregnant women diagnosed with measles should receive symptomatic care. No 
specific treatment is available.
Recommendations for neonates born to women ill with measles:
• Because of the increased risk of severe disease in neonates born to mothers who 
have measles within 10 days of delivery, obstetric health care providers need to 
ensure that the pediatrician caring for the neonate is aware of the potential for 
congenital measles. It is recommended that infants (younger than 12 months of age) 
with exposure to measles receive measles immune globulin intramuscularly at a 
dose of 0.5 mL/kg of body weight (max = 15 mL).3
• Limited data are available regarding whether well neonates born to mothers who 
are ill with measles need to be separated from their mothers. Clinicians should 
discuss the specific situation with infection control and public health experts to 
weigh the benefits and risks of isolating the neonate from the mother until she is no 
longer infectious (4 days after onset of her rash).
Acknowledgments
The authors thank Dr. Greg Wallace, Lead, for CDC’s Measles, Mumps, Rubella, and Polio Team, for his helpful 
comments on the manuscript.
The findings and conclusions in this report are those of the authors and do not necessarily represent the official 
position of the Centers for Disease Control and Prevention.
REFERENCES
1. Centers for Disease Control and Prevention (CDC). [Retrieved March 20, 2015] Measles cases and 
outbreaks. Available at: http://www.cdc.gov/measles/cases-outbreaks.html.
2. Parker Fiebelkorn A, Redd SB, Gallagher K, Rota PA, Rota J, Bellini W, et al. Measles in the 
United States during the post-elimination era. J Infect Dis. 2010; 202:1520–1528. [PubMed: 
20929352] 
3. McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Centers for Disease Control and Prevention. 
Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary 
Rasmussen and Jamieson Page 7













recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm 
Rep. 2013; 62:1–34. [PubMed: 23760231] 
4. Ogbuanu IU, Zeko S, Chu SY, Muroua C, Gerber S, De Wee R, et al. Maternal, fetal, and neonatal 
outcomes associated with measles during pregnancy: Namibia, 2009–2010. Clin Infect Dis. 2014; 
58:1086–1092. [PubMed: 24457343] 
5. Eberhart-Phillips JE, Frederick PD, Baron RC, Mascola L. Measles in pregnancy: a descriptive 
study of 58 cases. Obstet Gynecol. 1993; 82:797–801. [PubMed: 8414327] 
6. Ali ME, Albar HM. Measles in pregnancy: maternal morbidity and perinatal outcome. Int J 
Gynaecol Obstet. 1997; 59:109–113. [PubMed: 9431872] 
7. Campbell H, Andrews N, Brown KE, Miller E. Review of the effect of measles vaccination on the 
epidemiology of SSPE. Int J Epidemiol. 2007; 36:1334–1348. [PubMed: 18037676] 
8. Siegel M, Fuerst HT. Low birth weight and maternal virus diseases. A prospective study of rubella, 
measles, mumps, chickenpox, and hepatitis. JAMA. 1966; 197:680–684. [PubMed: 5952908] 
9. Siegel M, Fuerst HT, Peress NS. Comparative fetal mortality in maternal virus diseases. A 
prospective study on rubella, measles, mumps, chicken pox, and hepatitis. N Engl J Med. 1966; 
274:768–771. [PubMed: 17926883] 
10. Jespersen CS, Littauer J, Sagild U. Measles as a cause of fetal defects. A retrospective study of tem 
measles epidemics in Greenland. Acta Paediatr Scand. 1977; 66:367–372. [PubMed: 559402] 
11. Siegel M. Congenital malformations following chickenpox, measles, mumps, and hepatitis. Results 
of a cohort study. JAMA. 1973; 226:1521–1524. [PubMed: 4800931] 
12. Charlier C, Hourrier S, Leruez-Ville M, Zahar JR, Floret D, Salomon LJ, et al. Polyvalent 
immunoglobulins in neonates after perinatal exposure to measles: benefits and long-term tolerance 
of immunoglobulins. J Infect. 2015 Jan 22. [Epub ahead of print]. 
13. Haas DM, Flowers CA, Congdon CL. Rubella, rubeola, and mumps in pregnant women: 
susceptibilities and strategies for testing and vaccinating. Obstet Gynecol. 2005; 106:295–300. 
[PubMed: 16055578] 
14. Kennedy CM, Burns BA, Ault KA. Does rubella immunity predict measles immunity? A 
serosurvey of pregnant women. Infect Dis Obstet Gynecol. 2006; 2006:13890. [PubMed: 
17485795] 
15. Integrating immunizations into practice. Committee Opinion No. 558. American College of 
Obstetricians and Gynecologists. Obstet Gynecol. 2013; 121:897–903. [PubMed: 23635707] 
16. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention 
(CDC). Immunization of health-care personnel: recommendations of the advisory committee on 
immunization practices (ACIP). MMWR Recomm Rep. 2011; 60:1–45.
17. Dyer I. Measles complicating pregnancy. South Med J. 1940; 33:601–604.
18. Christensen PE, Schmidt H, Bang HO, Andersen V, Jordal B, Jensen O. An epidemic of measles in 
southern Greenland, 1951; measles in virgin soil. II. The epidemic proper. Acta Med Scand. 1953; 
144:430–449. [PubMed: 13050347] 
19. Yasunaga H, Shi Y, Takeuchi M, Horiguchi H, Hashimoto H, Matsuda S, et al. Measles-related 
hospitalizations and complications in Japan, 2007–2008. Intern Med. 2010; 49:1965–1970. 
[PubMed: 20847499] 
20. Stahl JP, Salmon D, Bruneel F, Caumes E, Freymuth F, Bru JP, et al. Adult patients hospitalized 
for measles in France, in the 21st century. Med Mal Infect. 2013; 43:410–416. [PubMed: 
24050842] 
21. Ali AA, Abdelhameed O, Abdallah TM. Case-fatality rate associated with measles during 
pregnancy in Kassala, eastern Sudan. Int J Gynaecol Obstet. 2014; 124:261–262. [PubMed: 
24332680] 
Rasmussen and Jamieson Page 8














Number of measles cases in the United States by year, 2001–present (April 3, 2015). Red 
bar indicates partial data. *Provisional data reported to Centers for Disease Control and 
Prevention’s National Center for Immunization and Respiratory Diseases through April 3, 
2015. Modified from Centers for Disease Control and Prevention. Measles Cases and 
Outbreaks. Atlanta (GA): Centers for Disease Control and Prevention; 2015. Available at: 
http://www.cdc.gov/measles/cases-outbreaks.html.
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Table 1
Summary of Case Series and Cohort Studies of Measles in Pregnancy
Year Cases
Occurred First Author Location
Pregnant Women With
Measles Control Group
1938–1939 Dyer17 Oklahoma 24 None





Jespersen10 Greenland Total of 368 pregnant women, 327 
with pregnancy information; 252 
neonates with clinical examination
No formal control group, but compared 
outcomes with baseline rates during same 
time period
1957–1964 Siegel8,9,11 New York (NY) 65 pregnant women with measles 
with information on outcomes, 60 
neonates born to women with 
measles
Pregnant women without measles; 62 
neonates born to women without measles 
matched on obstetric service, maternal 
age, race, gravidity, date of last menstrual 
period
1988–1991 Eberhart-Phillips5 Los Angeles (CA) 58 748 nonpregnant women with measles of 
similar age reported to county health 
department during same period as cases
1993 Ali6 Saudi Arabia 40 37 nonpregnant women with measles; 120 
pregnant women without measles
2007–2008 Yasunaga19 Japan 31 None
2009–2011 Ogbuanu4 Namibia 55; 19% HIV-positive 3 pregnant women without measles for 
each case; 15% HIV-positive
2010–2011 Stahl20 France 20 pregnant women 440 nonpregnant persons hospitalized 
during the same time period
2011–2012 Ali21 Eastern Sudan 61 None
Maternal Outcome Fetal or Neonatal Outcome Congenital Defects
1 epistaxis; 1 postpartum sepsis; no maternal 
deaths
1 spontaneous abortion at 18 wk of gestation; 2 
preterm deliveries at 33 and 35 wk; among 24 
liveborn infants, (including 1 set of twins), one 
infant death at 1 mo of age (infant died from 
pneumonia)
No mention of congenital defects 
among 24 liveborn neonates
No increased lung complications; heart failure 
more common among pregnant and postpartum 
women
7 spontaneous abortion; 6 preterm delivery with 
3 neonatal deaths. Among term neonates, 2 
deaths within 24 h of life
No congenital defects among 69 
liveborn neonates
Among 20 women infected in first 8 wk of 
pregnancy, 10 (50%) had spontaneous abortion; 
6/64 (9%) of women infected in 1st trimester had 
fetal deaths; rates of low birth weight (11%) and 
infant mortality (11%) higher than typically seen 
during time period
Among 300 liveborn neonates, 8 
(2.7%) had congenital malformations, 
a rate not higher than expected. 5/58 
(9%) of neonates exposed in the 1st 
trimester had severe congenital 
malformations, but no specific pattern 
of malformations noted
Increased frequency of low birth weight in 
neonates born to women with measles (17%) vs 
neonates born to women without measles (3%); 
no differences in pregnancy loss rates
Rate of congenital defects similar in 
neonates born to mothers with measles 
vs controls (1.7% vs 1.6%)
Among pregnant women: 35 (60%) hospitalized; 
15 (26%) had pneumonia; 2 (3%) died; vs 
controls, pregnant women more likely to be 
hospitalized (RR 1.8; 95% CI 1.5–2.3), to 
develop pneumonia (RR 2.6; 95% CI 1.6–4.3), 
and to die (RR 6.4; 95% CI 1.2–34.5)
Among 58 pregnancies, there were 37 term 
deliveries, 3 therapeutic abortions, 5 spontaneous 
abortions, and 13 premature deliveries. 29 (50%) 
of pregnancies ended within 14 d of the onset of 
measles rash
2 congenital defects; slight clubfoot in 
neonate born to mother infected at 39 
wk of gestation; polydactyly in 
neonate born to mother infected at 37 
wk of gestation. No defects in 5 
liveborn neonates born to mothers 
infected in the 1st trimester
Vs nonpregnant women, pregnant women more 
likely to be hospitalized (80% vs 8%; P<.001), 
have high fever (33% vs 11%, P=.04), have 
elevated liver enzymes (65% vs 32%, P<.008). 
Among pregnant women, 4 (10%) had 
Vs pregnant women without measles, neonates 
born to women with measles were more likely to 
be born preterm (25% vs 6.7%, P=.003), to be 
admitted to the neonatal intensive care unit 
(17.5% vs 1.7%, P<.001), and to have a longer 
No difference in rate of congenital 
defects among neonates born to 
women with and without measles 
during pregnancy
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Maternal Outcome Fetal or Neonatal Outcome Congenital Defects
pneumonia, 2 requiring oxygen therapy and 1 
required mechanical ventilation vs 5% (2) with 
pneumonia among nonpregnant controls (P=.4), 
neither required oxygen or mechanical 
ventilation
stay in the neonatal intensive care unit (P<.001). 
Rates of spontaneous abortion, intrauterine fetal 
demise and neonatal mortality higher in pregnant 
women with measles vs pregnant women without 
measles, but findings not statistically significant
All hospitalized (hospital-based case 
ascertainment); 1 pneumonia, 1 intestinal 
complication, 1 conjunctivitis
10 (32.3%) spontaneous abortions or fetal deaths No mention of congenital defects 
among 21 liveborn neonates
53 (96%) hospitalized; diarrhea (60%), 
pneumonia (40%), encephalitis (5%); 5 deaths 
including 3 among HIV-positive and 2 with 
unknown HIV status. After adjustment for 
maternal age, vs pregnant women without 
measles, pregnant women with measles were 
more likely to die (RR 9.6; 95% CI 1.3–70.0)
Vs pregnant women without measles, pregnant 
women with measles were at increased risk for 
spontaneous abortion (adjusted RR 5.9; 95% CI 
1.8–19.7), intrauterine fetal death (adjusted RR 
9.0; 95% CI 1.2–65.5) and low birth weight 
(adjusted RR 3.5; 95% CI 1.5–8.2).
No congenital defects among 31 
liveborn neonates
All hospitalized (hospital-based case 
ascertainment); no deaths; no pregnant women 
with severe illness (admission to intensive care 
unit), vs 6% of nonpregnant cases; 1 pneumonia 
and elevated serum transaminases, 2 pneumonia 
only, 10 with elevated serum transaminases only, 
7 with a “nonstandard rash”
9 outcomes of pregnancy “favorable,” 1 
spontaneous abortion, 10 outcomes of pregnancy 
not documented
No mention of congenital defects in 9 
patients with “favorable” outcomes
All hospitalized (hospital-based case 
ascertainment); 11 maternal deaths (18.0%); 
reported causes of death were pneumonia (9), 
encephalitis (1), intracranial hemorrhage (1)
Among 53 women followed until delivery, 6 
(11.3%) spontaneous abortions, 4 (7.5%) preterm 
births, 3 (5.7%) fetal deaths
No mention of congenital defects 
among 44 liveborn neonates
RR, relative risk; CI, confidence interval; HIV, human immunodeficiency virus.
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